Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting
Apr 24, 2018
PDF 284.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Apr 18, 2018
PDF 283.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference
Mar 26, 2018
PDF 277.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting
Mar 15, 2018
PDF 283.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update
Mar 8, 2018
PDF 294.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update
Mar 6, 2018
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
Mar 2, 2018
PDF 280.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology
Feb 21, 2018
PDF 282.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018
Feb 2, 2018
PDF 285.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018
Jan 24, 2018
PDF 283.2 KB Add to Briefcase
View Summary TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies
Jan 8, 2018
PDF 285.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 8, 2018
PDF 277.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting
Dec 11, 2017
PDF 289.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting
Dec 8, 2017
PDF 326.5 KB Add to Briefcase
View Summary TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma
Nov 27, 2017
PDF 282.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results
Nov 8, 2017
PDF 291.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update
Nov 6, 2017
PDF 276.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting
Nov 1, 2017
PDF 329.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis
Oct 31, 2017
PDF 277.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 27, 2017
PDF 284.0 KB Add to Briefcase
Showing 1-20 of 229 Page: 1 2 3 4 5 ... 12  Next 20
Add to Briefcase = add release to Briefcase